Skip to main content

Month: March 2026

Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform

Visit Nexentis at: www.nexentistech.com Neve Yarak, Israel, March 13, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, is proud to announce the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company’s recent rebranding from N2OFF, Inc., and underscores its commitment to advancing mitochondrial biology for breakthroughs in precision oncology and inflammatory metabolic diseases. The newly launched website serves as a comprehensive hub for stakeholders, including investors, partners, and the scientific community, to explore Nexentis’ transformative platform. Key features include detailed insights into the...

Continue reading

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline  Access the Akari CEO Corner here TAMPA, Fla. and LONDON, March 13, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala reflecting on his first year leading the Company and the strategic progress achieved during that time. Over the past year under Abizer Gaslightwala’s leadership, Akari Therapeutics has sharpened its strategic focus and advanced the development of its proprietary PH1 ADC payload platform. In the latest CEO Corner, Mr. Gaslightwala highlights...

Continue reading

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY (a public company incorporated with limited liability in Ireland) WISDOMTREE FTSE 100 2X DAILY SHORT SECURITIES ISIN: IE00B94QKF15

13 March 2026 LEI: 2138003QW2ZAYZODBU23 LSE Code: 2UKS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE FTSE 100 2X DAILY SHORT SECURITIESISIN: IE00B94QKF15PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. If you have sold or transferred all of your WisdomTree FTSE 100 2x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee...

Continue reading

ParaZero Secures a New Order for DefendAir Counter-UAS Systems from Israeli Defense Entity

Kfar Saba, Israel, March 13, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced it has received a new purchase order from an Israeli defense entity for its DefendAir Counter-Unmanned Aerial Systems (Counter-UAS) solution. This new order reinforces the growing trust and operational reliance on ParaZero’s DefendAir platform by multiple strategic defense entities within Israeli defense ecosystem. The order includes the delivery of an evaluation kit including DefendAir’s net pods live exercise and training to support rapid operational deployment and maximize readiness. DefendAir is a multi-layered soft-hard kill Counter-UAS system that deploys...

Continue reading

Greenland Energy and Pelican Acquisition Corporation (NASDAQ: PELI) Appoints Ashiq Merchant, former BP executive, as Chief Financial Officer to Drive Transition to Public Markets and Advance World-Class Arctic Operations

New financial leadership brings 25 years of multinational experience at BP across upstream and downstream businesses in multiple international jurisdictions, including the Middle East and North America HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) — The leadership team behind the formation of Greenland Energy Company (“Greenland”) today announced the appointment of Ashiq Merchant as Chief Financial Officer of the post-merger company. Merchant joins the executive team at a pivotal moment as the company advances its proposed business combination with Pelican Acquisition Corporation (NASDAQ: PELI). Upon the expected closing of the transaction following the March 17, 2026, Extraordinary General Meeting of Shareholders, the combined company will trade on the Nasdaq under the ticker symbol “GLND”. In his role as CFO, Merchant will oversee...

Continue reading

U.S. Energy Corp. Reports 2025 Results and Highlights Transformation into Integrated Industrial Gas, Energy, and Carbon Management Platform

HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”) today reported financial and operating results for the fourth quarter and year ended December 31, 2025, while highlighting the advancement of the Company’s strategic transformation into a fully integrated industrial gas, energy, and carbon management platform.  MANAGEMENT COMMENTS “2025 was a transformational year for U.S. Energy, one defined by purposeful execution and a forward-looking vision,” said Ryan Smith, Chief Executive Officer of U.S. Energy Corp. “We deliberately optimized and monetized our conventional oil and gas portfolio to fund the development of something far more valuable: a fully integrated industrial gas, energy, and carbon management platform that we believe is fundamentally...

Continue reading

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2  Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded therapeutic window and commercially viable yield Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 demonstrates multi-arm anti-tumor activity for both IM1240 and IM1305 Total Cash Position of $9.5 million as of December 31, 2025, expected to provide runway into 2027 REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed...

Continue reading

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026 Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune...

Continue reading

WeRide Inc. Announces Results of Extraordinary General Meeting, Class A Meeting and Class B Meeting

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEx: 0800), a global leader in autonomous driving technology, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of extraordinary general meeting, notice of Class A meeting and notice of Class B meeting, each dated February 6, 2026, Beijing time, have been adopted at the meetings held in Guangzhou, Guangdong Province, China today. After the adoption of the Proposed Resolutions, all corporate authorizations and actions contemplated thereunder are approved, including, among other things, that (i) the Company’s existing memorandum and articles of associations are amended and restated by their deletion in their entirety and by the substitution...

Continue reading

Activate Energy Acquisition Corp. Announces Filing of Annual Report for Year Ended December 31, 2025

GRAND CAYMAN, Cayman Islands, March 13, 2026 (GLOBE NEWSWIRE) — Activate Energy Acquisition Corp. (NASDAQ: AEAQ) (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). Key Highlights from the Annual Report Include:Cash and Investments: Approximately $ 230,556,356 held in the trust account, invested in U.S. government securities or money market funds meeting certain conditions under Rule 2a-7 of the Investment Company Act.Operating Results: Net income of $ 300,371...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.